In the article by Amersi and coworkers on how activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestines, beginning on page 638 of the February 1, 2008, issue of Clinical Cancer Research, Figure 5 should have appeared in color, as shown below.

Fig. 5.
Fig. 5. Representative immunohistochemistry staining for CCR9. Representative immunohistochemistry staining using anti-CCR9 antibody for CCR9 expression in melanoma small intestinal metastases specimens demonstrating strong immunoreactivity (A and B). Representative staining of negative control tissues is shown in C.
View largeDownload slide

Representative immunohistochemistry staining for CCR9. Representative immunohistochemistry staining using anti-CCR9 antibody for CCR9 expression in melanoma small intestinal metastases specimens demonstrating strong immunoreactivity (A and B). Representative staining of negative control tissues is shown in C.

Fig. 5.
Fig. 5. Representative immunohistochemistry staining for CCR9. Representative immunohistochemistry staining using anti-CCR9 antibody for CCR9 expression in melanoma small intestinal metastases specimens demonstrating strong immunoreactivity (A and B). Representative staining of negative control tissues is shown in C.
View largeDownload slide

Representative immunohistochemistry staining for CCR9. Representative immunohistochemistry staining using anti-CCR9 antibody for CCR9 expression in melanoma small intestinal metastases specimens demonstrating strong immunoreactivity (A and B). Representative staining of negative control tissues is shown in C.

Close modal
View Original Article
American Association for Cancer Research
2008